{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T20:45:34Z","timestamp":1786221934827,"version":"build-2736575974"},"reference-count":34,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020841","name":"Envision","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020841","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004948","name":"Astellas Pharma Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","eu-focus.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Focus"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.euf.2026.01.010","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T12:32:33Z","timestamp":1771417953000},"page":"393-402","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and Safety of Mirabegron in Patients with Overactive Bladder and Cardiovascular Comorbidities: A Post Hoc Analysis of Randomised Trials"],"prefix":"10.1016","volume":"12","author":[{"given":"Amy","family":"Lockefeer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianne","family":"Schild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swapneel","family":"Anaokar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikkel","family":"Fode","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euf.2026.01.010_b0005","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/nau.22609","article-title":"Do we need a new definition of the overactive bladder syndrome? ICI-RS 2013","volume":"33","author":"Drake","year":"2014","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.euf.2026.01.010_b0010","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/nau.22295","article-title":"The prevalence of lower urinary tract symptoms (LUTS) and overactive bladder (OAB) by racial\/ethnic group and age: results from OAB-POLL","volume":"32","author":"Coyne","year":"2013","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.euf.2026.01.010_b0015","first-page":"1","article-title":"The prevalence and forecast prevalence of overactive bladder in the Medicare population","volume":"12","author":"Puckrein","year":"2019","journal-title":"Clin Med Insights Urol"},{"key":"10.1016\/j.euf.2026.01.010_b0020","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1002\/nau.24894","article-title":"What is the real burden of the overactive bladder? Results from a national prevalence study","volume":"41","author":"Santander","year":"2022","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.euf.2026.01.010_b0025","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.urology.2012.04.004","article-title":"Effect of bothersome overactive bladder symptoms on health-related quality of life, anxiety, depression, and treatment seeking in the United States: results from EpiLUTS","volume":"80","author":"Milsom","year":"2012","journal-title":"Urology"},{"key":"10.1016\/j.euf.2026.01.010_b0030","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1111\/j.1464-410X.2010.10013.x","article-title":"The impact of overactive bladder on mental health, work productivity and health-related quality of life in the UK and Sweden: results from EpiLUTS","volume":"108","author":"Coyne","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2026.01.010_b0035","unstructured":"Harding CK, Lapitan MC, Arlandis S, et al. EAU guidelines on management of non-neurogenic female lower urinary tract symptoms. Limited update March 2023. https:\/\/d56bochluxqnz.cloudfront.net\/documents\/full-guideline\/EAU-Guidelines-on-Non-neurogenic-Female-LUTS-2024.pdf."},{"key":"10.1016\/j.euf.2026.01.010_b0040","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.eururo.2008.06.047","article-title":"The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis","volume":"54","author":"Chapple","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2026.01.010_b0045","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1097\/JU.0000000000002804","article-title":"Dementia associated with anticholinergic drugs used for overactive bladder: a nested case-control study using the French National Medical-Administrative Database","volume":"208","author":"Malcher","year":"2022","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2026.01.010_b0050","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/j.euf.2021.10.009","article-title":"Receipt of overactive bladder drugs and incident dementia: a population-based case-control study","volume":"8","author":"Matta","year":"2022","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euf.2026.01.010_b0055","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1111\/ijcp.12433","article-title":"Safety and tolerability of the \u03b23-adrenoceptor agonist mirabegron, for the treatment of overactive bladder: results of a prospective pooled analysis of three 12-week randomised phase III trials and of a 1-year randomised phase III trial","volume":"68","author":"Nitti","year":"2014","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.euf.2026.01.010_b0060","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.eururo.2012.10.016","article-title":"Efficacy and tolerability of mirabegron, a \u03b23-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial","volume":"63","author":"Khullar","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2026.01.010_b0065","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.urology.2013.02.077","article-title":"A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the \u03b23 adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder","volume":"82","author":"Herschorn","year":"2013","journal-title":"Urology"},{"key":"10.1016\/j.euf.2026.01.010_b0070","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.eururo.2019.10.002","article-title":"Efficacy, safety, and tolerability of mirabegron in patients aged \u226565 yr with overactive bladder wet: a phase IV, double-blind, randomised, placebo-controlled study (PILLAR)","volume":"77","author":"Wagg","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2026.01.010_b0075","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.jash.2018.08.001","article-title":"Cardiovascular safety of mirabegron: analysis of an integrated clinical trial database of patients with overactive bladder syndrome","volume":"12","author":"White","year":"2018","journal-title":"J Am Soc Hypertens"},{"key":"10.1016\/j.euf.2026.01.010_b0080","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/nau.23852","article-title":"Mirabegron as a treatment for overactive bladder symptoms in men (MIRACLE study): efficacy and safety results from a multicenter, randomized, double-blind, placebo-controlled, parallel comparison phase IV study","volume":"38","author":"Shin","year":"2019","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.euf.2026.01.010_b0085","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.juro.2012.10.017","article-title":"Results of a randomized phase III trial of mirabegron in patients with overactive bladder","volume":"189","author":"Nitti","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2026.01.010_b0090","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1111\/bju.12649","article-title":"Phase III, randomised, double-blind, placebo-controlled study of the \u03b23-adrenoceptor agonist mirabegron, 50 mg once daily, in Japanese patients with overactive bladder","volume":"113","author":"Yamaguchi","year":"2014","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2026.01.010_b0095","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/luts.12053","article-title":"Efficacy and safety of the selective \u03b23-adrenoceptor agonist mirabegron in Japanese patients with overactive bladder: a randomized, double-blind, placebo-controlled, dose-finding study","volume":"7","author":"Yamaguchi","year":"2015","journal-title":"Low Urin Tract Symptoms"},{"key":"10.1016\/j.euf.2026.01.010_b0100","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/bju.13882","article-title":"Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study)","volume":"120","author":"Herschorn","year":"2017","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2026.01.010_b0105","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.eururo.2014.02.012","article-title":"Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony)","volume":"67","author":"Abrams","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2026.01.010_b0110","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1007\/s00192-013-2042-x","article-title":"A phase II dose-ranging study of mirabegron in patients with overactive bladder","volume":"24","author":"Chapple","year":"2013","journal-title":"Int Urogynecol J"},{"key":"10.1016\/j.euf.2026.01.010_b0115","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/nau.22645","article-title":"Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a \u03b23-adrenoceptor agonist, in patients with overactive bladder in Asia","volume":"34","author":"Kuo","year":"2015","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.euf.2026.01.010_b0120","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1177\/1756287215589250","article-title":"The efficacy and safety of mirabegron compared with solifenacin in overactive bladder patients dissatisfied with previous antimuscarinic treatment due to lack of efficacy: results of a noninferiority, randomized, phase IIIb trial","volume":"7","author":"Batista","year":"2015","journal-title":"Ther Adv Urol"},{"key":"10.1016\/j.euf.2026.01.010_b0125","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1007\/s40264-021-01095-7","article-title":"Cardiovascular risk in users of mirabegron compared with users of antimuscarinic treatments for overactive bladder: findings from a non-interventional, multinational, cohort study","volume":"44","author":"Hoffman","year":"2021","journal-title":"Drug Saf"},{"key":"10.1016\/j.euf.2026.01.010_b0130","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0205640","article-title":"Cardiovascular risk profile in individuals initiating treatment for overactive bladder \u2014 challenges and learnings for comparative analysis using linked claims and electronic medical record databases","volume":"13","author":"Vonesh","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.euf.2026.01.010_b0135","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1345\/aph.1S054","article-title":"Mirabegron: \u03b23-adrenergic receptor agonist for the treatment of overactive bladder","volume":"47","author":"Bridgeman","year":"2013","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.euf.2026.01.010_b0140","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1111\/iju.13218","article-title":"Real-world cardiovascular assessment of mirabegron treatment in patients with overactive bladder and concomitant cardiovascular disease: results of a Japanese post-marketing study","volume":"23","author":"Katoh","year":"2016","journal-title":"Int J Urol"},{"key":"10.1016\/j.euf.2026.01.010_b0145","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1177\/1062860611413456","article-title":"Effect of illness severity and comorbidity on patient safety and adverse events","volume":"27","author":"Naessens","year":"2012","journal-title":"Am J Med Qual"},{"key":"10.1016\/j.euf.2026.01.010_b0150","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s40266-019-00674-9","article-title":"Relative risk of adverse events and treatment discontinuations between older and non-older adults treated with antimuscarinics for overactive bladder: a systematic review and meta-analysis","volume":"36","author":"Usmani","year":"2019","journal-title":"Drugs Aging"},{"key":"10.1016\/j.euf.2026.01.010_b0155","doi-asserted-by":"crossref","first-page":"A294","DOI":"10.1016\/j.jval.2014.03.1713","article-title":"Understanding MID for micturition frequency, a pivotal endpoint for OAB studies","volume":"17","author":"Pinto","year":"2014","journal-title":"Value Health"},{"key":"10.1016\/j.euf.2026.01.010_b0160","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/luts.12339","article-title":"Cardiovascular safety of mirabegron add-on therapy to tamsulosin for the treatment of overactive bladder in men with lower urinary tract symptoms: a post hoc analysis from the MATCH study","volume":"13","author":"Katoh","year":"2021","journal-title":"Low Urin Tract Symptoms"},{"key":"10.1016\/j.euf.2026.01.010_b0165","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.eururo.2015.09.007","article-title":"Cardiovascular safety of \u03b23-adrenoceptor agonists for the treatment of patients with overactive bladder syndrome","volume":"69","author":"Rosa","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2026.01.010_b0170","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.euf.2023.04.001","article-title":"Predicting mirabegron treatment response in patients with overactive bladder: a post hoc analysis of data from clinical trials","volume":"9","author":"Matta","year":"2023","journal-title":"Eur Urol Focus"}],"container-title":["European Urology Focus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456926000106?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456926000106?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T20:35:01Z","timestamp":1786221301000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405456926000106"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2405456926000106"],"URL":"https:\/\/doi.org\/10.1016\/j.euf.2026.01.010","relation":{},"ISSN":["2405-4569"],"issn-type":[{"value":"2405-4569","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety of Mirabegron in Patients with Overactive Bladder and Cardiovascular Comorbidities: A Post Hoc Analysis of Randomised Trials","name":"articletitle","label":"Article Title"},{"value":"European Urology Focus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euf.2026.01.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}